期刊
VACCINE
卷 23, 期 50, 页码 5708-5724出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2005.07.046
关键词
vaccines; SARS; influenza; pneumococcal infection; Streptococcus pneumoniae; Haemophilus influenzae; Hib; Respiratory Syncitial Virus; RSV; parainfluenza viruses; PIV; bronchiolitis
Worldwide, acute respiratory infections (ARls) constitute the leading cause of acute illnesses, being responsible for nearly 4 million deaths every year, mostly in young children and infants in developing countries. The main infectious agents responsible for ARIs include influenza virus, respiratory syncytial virus (RSV), parainfluenza virus type 3 (PIV-3), Streptococcus pneumoniae and Haemophilus influenzae. While effective vaccines against influenza, H. inflitenzae type b (Hib) and S. pneumoniae infections have been available for several years, no vaccine is available at present against illnesses caused by RSV, PIV-3, metapneurnovirus or any of the three novel coronaviruses. In addition, the threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines with broader spectrum of efficacy, which could provide immunity against an avian influenza virus pandemic. This article reviews the state of the art in vaccine R&D against ARIs and attempts to address these basic public health questions. (c) 2005 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据